Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

医学 内科学 危险系数 荟萃分析 置信区间 循环肿瘤细胞 肿瘤科 入射(几何) 科克伦图书馆 优势比 阶段(地层学) 癌症 食管癌 转移 光学 物理 生物 古生物学
作者
Yiding Li,Guiling Wu,Wanli Yang,Xiaoqian Wang,Lili Duan,Liaoran Niu,Yujie Zhang,Jinqiang Liu,Liu Hong,Daiming Fan
出处
期刊:Research Square - Research Square [Research Square (United States)]
标识
DOI:10.21203/rs.3.rs-20428/v2
摘要

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumour in the world, which is still the primary cause of tumour-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding active and effective treatment. Recently, circulating tumour cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined using the CellSearch System in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as effect values. Results: In total, 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher incidence of CTCs compared with the I/II group (OR=1.36, 95% CI (0.68,2.71), I 2 =0%). Incidence of CTCs was higher among patients on T3/T4 stage (OR=2.92, 95% CI (1.31,6.51), I 2 =0%) and distant metastasis group (OR=5.18, 95% CI (2.38,11.25), I 2 =0%) compared to patients on T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR =2.83, 95% CI (1.99,4.03), I 2 =0%) and relapse-free survival (RFS) (HR =4.71, 95% CI (2.73,8.13), I 2 =0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR =1.99, 95% CI (1.73,2.29), I 2 =60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs from PB of EC patients determined using the CellSearch System are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木木 12完成签到,获得积分10
刚刚
文静凝芙完成签到,获得积分10
刚刚
活泼雪莲发布了新的文献求助10
1秒前
可乐大侠完成签到 ,获得积分10
1秒前
萌萌2完成签到,获得积分10
1秒前
慈祥的鸿煊完成签到 ,获得积分10
2秒前
fantasy的应助被369ninja采纳,获得10
3秒前
王不凡完成签到 ,获得积分10
3秒前
Jeffrey完成签到,获得积分10
3秒前
蝈蝈完成签到,获得积分10
4秒前
雪山大地发布了新的文献求助10
5秒前
Echo完成签到,获得积分0
8秒前
JIANG完成签到,获得积分10
10秒前
ARIA完成签到 ,获得积分0
10秒前
群山完成签到 ,获得积分10
11秒前
mongmong完成签到 ,获得积分10
12秒前
13秒前
春夏完成签到 ,获得积分10
13秒前
卢彦冬完成签到,获得积分10
15秒前
16秒前
冷静以山完成签到 ,获得积分10
20秒前
飞儿完成签到 ,获得积分10
22秒前
369ninja发布了新的文献求助10
22秒前
兴奋的惮完成签到,获得积分10
23秒前
进击的牛马完成签到,获得积分10
23秒前
游01完成签到 ,获得积分10
25秒前
打打的应助被活泼雪莲采纳,获得10
27秒前
zhuangbaobao完成签到,获得积分10
27秒前
28秒前
个性怡完成签到 ,获得积分10
28秒前
深情的乐萱完成签到,获得积分10
28秒前
雪山大地发布了新的文献求助10
30秒前
失眠的寄云完成签到,获得积分10
33秒前
33秒前
O_0完成签到 ,获得积分10
33秒前
WQ完成签到,获得积分10
33秒前
莹莹大王发布了新的文献求助10
38秒前
落月无痕完成签到,获得积分10
40秒前
win050532完成签到 ,获得积分10
41秒前
吃饭打肯德基完成签到 ,获得积分10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166550
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750720
捐赠科研通 7757357
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553523
邀请新用户注册赠送积分活动 2473904